Vertex Pharmaceuticals (VRTX +4.8%) finishes higher today after saying it's entered into a non-exclusive agreement with GlaxoSmithKline (GSK) to conduct a Phase 2 study of an all-oral regimen for the treatment of hepatitis C containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and GSK's NS5A inhibitor GSK2336805. The study is expected to begin in early 2013, pending discussions with regulatory authorities.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs